Pharmaceutical intermediates
Dabigatran etexilate mesylate Intermediates
3 pharmaceutical intermediates for Dabigatran etexilate mesylate. Indication: Venous Thromboembolism (VTE); Embolism; Stroke; Pulmonary Embolism; Venous Thrombosis.
About Dabigatran etexilate mesylate
- Originator
- Boehringer Ingelheim
- Indication
- Venous Thromboembolism (VTE); Embolism; Stroke; Pulmonary Embolism; Venous Thrombosis
- Approved Date
- 06/21/2021
- DS/DP
- 09/07/2025
Available intermediates
3 intermediates currently listed for Dabigatran etexilate mesylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Dabigatran etexilate mesylate | 872728-81-9 | / | / |
| ethyl N-[3-amino-4-(methylamino)benzoyl]-N-pyridin-2-yl-beta-alaninate | 212322-56-0 | / | / |
| N-(4-cyanophenyl)-Glycine | 42288-26-6 | / | / |
Building toward Dabigatran etexilate mesylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →